Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
- A$4.78 million R&D tax rebate received for the year ended 31 March 2026
- Funds to support ACCENT, AMPLICITY, ACCENT-MINI and PRROSE programs
- Rebate relates primarily to narmafotinib clinical trial expenditure
- Lilly combination studies and AMP886 research also included
- Announcement does not disclose updated cash runway or total R&D spending
A$4.78 Million Rebate Adds Clinical Development Funding
Amplia Therapeutics (ASX:ATX) has received A$4,778,235.52 from the Australian Taxation Office under the Research and Development Tax Incentive, a sizeable cash inflow for a company funding a portfolio of early-stage oncology programs. The rebate relates to eligible expenditure incurred in the year ended 31 March 2026.
Amplia said the money will contribute to the progression of its ACCENT, AMPLICITY and ACCENT-MINI trials, as well as the PRROSE study, Lilly combination studies and other supporting R&D. The announcement does not state how much the rebate changes the company’s cash runway, nor whether the receipt was already reflected in previous financial expectations.
Narmafotinib Remains the Main Funding Focus
Most of the qualifying work involved the company’s FAK inhibitors, narmafotinib (AMP945) and AMP886, with the primary expenditure tied to ongoing clinical trials of narmafotinib in advanced pancreatic cancer. The ACCENT program, which earlier coverage linked to improved survival and response rates, remains a central beneficiary of the funding through the ACCENT trial data.
Amplia’s filing cites a 36% response rate and median overall survival of 11.1 months for narmafotinib in combination with gemcitabine and Abraxane in first-line advanced pancreatic cancer patients. Those figures are existing trial information, not new results from this announcement. The company also identifies AMPLICITY, which combines narmafotinib with FOLFIRINOX, as part of the continuing development program.
Lilly Studies Expand the Research Program
The rebate will also help fund the company’s Lilly trial collaboration, previously reported as a study combining narmafotinib with Lilly’s olomorasib in advanced non-small cell lung cancer. That work sits alongside Amplia’s pancreatic and ovarian cancer programs and reflects the range of research now being supported by the rebate.
The immediate significance is financial rather than clinical: Amplia has received cash linked to work already undertaken, but the announcement provides no new efficacy, safety or enrolment data. The next evidence will come from execution of the named trials and from the company’s subsequent reporting on cash use, development milestones and any further funding requirement.
Bottom Line?
The rebate reduces near-term funding pressure, but the key question is how long it supports the trial portfolio before another financing decision is needed.
Questions in the middle?
- How materially will the A$4.78 million receipt extend Amplia’s cash runway?
- What enrolment, safety or efficacy milestones will emerge from the ACCENT, AMPLICITY, ACCENT-MINI and PRROSE programs?
- Will future data support narmafotinib’s progression towards registration-enabling studies in pancreatic cancer or other indications?